Ads
related to: multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
Search results
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 4 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...
...Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep,...
Benzinga· 2 days agoResults from the MajesTEC-1 study show that, at a median follow-up of 30.4 months, patients treated...
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
BioPharma Dive via Yahoo Finance· 17 hours agoA study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 4 days agoAt a median follow-up of 21.8 months, the 12-month estimated PFS rates were 71% with BPd versus 51%...
Paul Mescal's mum shares cancer battle update
Digital Spy· 14 hours agoThe actor's mother, who has shared regular social media posts about her cancer journey, was first diagnosed with multiple myeloma in 2022, a cancer that...
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated ...
Benzinga· 2 days agoThe data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On...
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma - Blood...
Nature· 6 days agoB-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective ...
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
InvestorPlace· 9 hours agoThese 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks· 6 days agoThe FDA granted priority review designations to Sanofi's (SNY Quick QuoteSNY - Free Report) and Roche’s (RHHBY Quick QuoteRHHBY - Free Report) regulatory applications seeking expanded use of ...
‘Frances Oldham Kelsey, the FDA, and the Battle Against Thalidomide’ Review: The Noble Bureaucrat
The Wall Street Journal· 2 days agoBut virtually all of those cases were abroad: The drug never won approval as a sedative in the U.S....
